Teprotumumab improves proptosis, quality of life for adults with thyroid eye disease

Adults with thyroid eye disease assigned the human monoclonal antibody teprotumumab were significantly more likely to experience a meaningful improvement in proptosis after 21 weeks of treatment compared with those who received placebo, according to findings from a randomized controlled trial published in The New England Journal of Medicine.
“Other than highly invasive surgical procedures, patients with thyroid eye disease had no real treatment alternatives,” Raymond Douglas, MD, PhD, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, told

Full Story →